English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18369/20625 (89%)
Visitors : 16479095      Online Users : 171
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31751

    標題: Early Erythropoietin Administration does not Increase the Risk of Retinopathy in Preterm Infants
    作者: Chou, Hsin-Hsu
    Chung, Mei-Yung
    Zhou, Xiao-Guang
    Lin, Hung-Chih
    貢獻者: Ditmanson Med Fdn,Chia Yi Christian Hosp, Dept Pediat
    Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth
    Chang Gung Univ, Coll Med
    Nanjing Med Univ, Nanjing Childrens Hosp
    China Med Univ, Childrens Hosp
    China Med Univ, Sch Chinese Med
    關鍵字: erythropoietin
    retinopathy of prematurity
    日期: 2017-02
    上傳時間: 2018-11-30 15:55:20 (UTC+8)
    出版者: Elsevier Taiwan
    摘要: BACKGROUND: Erythropoietin (EPO) administration prevents anemia of prematurity and may be associated with a significant increase in the risk of retinopathy of prematurity (ROP) in preterm infants. Nonetheless, early EPO treatment may prevent damage following retinal neovascularization. The aim of this meta-analysis was to elucidate whether EPO administration increases the risk of ROP. METHODS: We searched MEDLINE, PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and the Cochrane Central Register of Controlled Trials with no language restrictions. Randomized controlled trials that reported the association between EPO treatment in preterm infants and ROP were eligible. All of the included studies were stratified into two groups according to the age of initiation of EPO treatment: before 8 days of age (early EPO), and 8-28 days of age (late EPO). RESULTS: Thirteen studies were identified that included a total of 1999 preterm infants. EPO administration did not increase the risk of ROP of any stage or Stage >= 3 (any relative risk: 0.99, 95% confidence interval: 0.84-1.16, p = 0.89; Stage >= 3 relative risk: 1.34, 95% confidence interval: 0.90-1.99, p = 0.15). This trend remained unchanged in both the early and late EPO groups. There did not seem to be any evidence of publication bias for outcomes as the funnel plots were symmetrical. CONCLUSION: EPO administration did not significantly increase the risk of ROP of any stage reported or Stage >= 3. Further clinical trials investigating the impact of EPO on ROP in premature infants should include all confounding factors to clarify this important issue. Copyright (c) 2016. Published by Elsevier B.V.
    關聯: Pediatrics and Neonatology, v.58, n.1, pp.48-56
    Appears in Collections:[生活應用與保健系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    j.pedneo.2016.03.006.pdf1129KbAdobe PDF0View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback